When a federal judge dismissed a whistleblower case against Novartis back in 2020, the court gave plaintiffs one last chance to prove the pharma giant bribed physicians to prescribe its multiple sclerosis drug Gilenya. On Tuesday, those efforts came up short.
US District Judge Kimba Wood of Southern New York ruled once again that former Novartis sales rep Steven Camburn’s complaint lacked sufficient detail to support claims that Novartis deployed a kickback scheme to boost Gilenya prescriptions.
Unlock this story instantly and join 150,200+ biopharma pros reading Endpoints daily — and it's free.
If you work in cancer biomarker and target research, chances are you use data from The Cancer Genome Atlas (TCGA) to help you make discoveries. This comprehensive and coordinated effort helps accelerate our understanding of the molecular causes of cancer through genomic analyses, including large-scale genome sequencing. TCGA covers 33 types of cancer with multi-omics data, such as RNA-seq, DNA-seq, copy number, microRNA-seq, and others. Detailed analyses of individual TCGA datasets, as well as pan-cancer meta-analysis, have revealed new cancer subtypes with important therapeutic implications. A key value here is the TCGA metadata. TCGA samples include extensive clinical metadata for diverse cancers. However, inconsistent terminology and formatting limit the utility of these data for pan-cancer...
Accusing Chief Minister V.D. Satheesan of falsely claiming that he met K.H. Mohammed Hussain, an accused in the MDMA case, only after he was injured in the police action during the Left Democratic...